Speakers
Frederick Appelbaum, MD
Institution: Fred Hutch Cancer Center
Dr. Fred Appelbaum studies the biology and treatment of leukemias, lymphomas and other blood cancers and sees patients with these disorders. He has made numerous landmark contributions to his field. Notably, he helped develop Fred Hutch’s renowned program in blood stem cell transplantation.
Bruce Blazar, MD
Institution: University of Minnesota, Medical School
Dr. Bruce Blazar received a BS degree from Rensselaer Polytechnic Institute and MD degree from Albany Medical College following which he obtained clinical training in pediatrics and hematology/oncology/blood and marrow transplantation at the University of Minnesota. He is a Regents Professor in the Department of Pediatrics and founding director of both the Clinical and Translational Science Institute and the Center for Translational Medicine.
Eliane Gluckman, MD, FRCP
Institution: Professor Emeritus of Paris-Cité University
As a physician, hematologist and Professor Emeritus of Paris-Cité University, Dr. Eliane Gluckman has a longstanding interest in the field of hematopoietic stem cell transplantation. Her research interests include hematopoietic cell transplantation for malignant and non-malignant hematological diseases, umbilical cord blood biology and transplantation, selection of hematopoietic cell donors and cord blood banks, with a particular focus on hereditary hematological diseases such as Fanconi Anemia and Sickle Cell Disease.
Hildegard Greinix, MD
Institution: Medical University of Vienna
Rick J. Jones, MD
Institution: Johns Hopkins Medicine
Richard J. Jones, MD is Professor of Oncology, Medicine, and Pathobiology, Associate Director of the Sidney Kimmel Cancer Center for Faculty and Program Development, as well as Director of the Bone Marrow Transplantation (BMT) and co-Director of the Hematologic Malignancies Programs at Johns Hopkins University. His major area of research interest is normal and malignant stem cell biology, especially the translation of promising findings from the laboratory to the clinic to improve the treatment of malignant and non-malignant blood disorders.
Judith Shizuru, MD, PhD
Institution: Stanford Medicine
Dr. Judith Shizuru is a member of the Stanford Blood and Marrow Transplantation (BMT) faculty, the Stanford Immunology Program and the Institute of Stem Cell Biology and Regenerative Medicine. She has attended on the BMT clinical service since 1997 and oversees a research laboratory.
Keith Sullivan, MD
Institution: Duke University Medical Center
Early on, Dr. Sullivan and the team at Fred Hutch Cancer Center developed a systematic investigative approach for the diagnosis and treatment of chronic graft-versus-host disease (GVHD), the major cause of late morbidity and non-relapse mortality following allogeneic stem cell transplantation (SCT).